Burden of pancreatic cancer and disease progression: Economic analysis in the US

Oncology

Volumn 70, Issue 1, 2006, Pages 71-80

  Chang, Stella ^a   Long, Stacey R ^b   Kutikova, Lucie ^c   Bowman, Lee ^c   Crown, William H ^d   Lyman, Gary H ^e  

^a MEDSTAT GROUP   (United States)

^b Medstat Inc   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Ingenix Inc   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Economic burden; Pancreatic cancer

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DATA BASE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN; PANCREAS CANCER; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADULT; AGED; ALGORITHMS; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); COST OF ILLNESS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; UNITED STATES;

EID: 33644896815     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091312     Document Type: Article

References (12)

1. Brown DM, Everhart JE: Cost of digestive diseases in the United States; in Everhart JE (ed): Digestive Diseases in the United States: Epidemiology and Impact. Washington, US Department of Health and Human Services, National Institutes of Health, 1994, NIH Publication 94-1447.
2. Wilson LS, Lightwood JM: Pancreatic cancer: total costs and utilization of health services. J Surg Oncol 1999;71:171-181.
3. Du W, Touchette D, Vaitkevicius VK, Peters WP, Shields AF: Cost analysis of pancreatic carcinoma treatment. Cancer 2000;89:1917-1924.
4. Brown ML, Riley GF, Schussler N, Etzioni R: Estimating health care costs related to cancer treatment from SEER-Medicare Data. Med Care 2002;40(8 suppl):IV-104-IV-117.
5. Gliemelius B, Hoffman K, Graf W, Haglund U, Nyren O, Pahlman L, Sjoden PO: Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995;6:267-274.
6. Brandabur JJ, Kozarek RA, Ball TJ, Hofer BO, Ryan JA, Traverso LW, Freeny PC, Lewis GP: Nonoperative versus operative treatment of obstructive jaundice in pancreatic cancer: cost and survival analysis. Am J Gastroenterol 1988;83:1132-1139.
7. Elixhauser A, Halpern M: Economic evaluations of gastric and pancreatic cancer. Hepatogastroenterology 1999;46:1206-1213.
8. D'Hoore W, Bouckaert A, Tilquin C: Practical considerations on the use of the Charlson Comorbidity Index with administrative databases. J Clin Epidemiol 1996;49:1429-1433.
9. Barnes CA. Disease staging: a clinically orientated dimension of case mix. Am Med Rec Assoc 1985;56:22-27.
10. Duan N: Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 1983;78:605-610.
11. American Cancer Society. Cancer Facts and Figures. 2003. http://www.cancer.org/docroot/STT/stt_0_2003.asp?sitearea=STT&level=1.
12. Flanders TY, Foulkes WD: Pancreatic adenocarcinoma: epidemiology and genetics. J Med Genet 1996;33:889-898.